2,6-Dimethylmescaline, or simply dimethylmescaline (DMe-M), also known as 2,6-dimethyl-3,4,5-trimethoxyphenethylamine, is a serotonin receptor modulator of the phenethylamine and scaline families related to mescaline. It is the 2,6-dimethyl derivative of mescaline.
The drug shows affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 45nM, 879nM, and 1,002nM, respectively). These affinities were 66-fold, 5.2-fold, and 7.7-fold higher than those of mescaline, respectively. The drug has not been tested in animals or humans.
2,6-Dimethylmescaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013. The source of the information cited by Trachsel and colleagues was a personal communication with David E. Nichols in 2010. It is not a controlled substance in Canada as of 2025.
See also Scaline PeMPEA (2,6-dimethoxymescaline) 2,6-Dibromomescaline 2,6-Dichloromescaline DOTMA (Julia; 3,6-dimethyl-DOM) Juno (6-methyl-DOM) Ganesha (3-methyl-DOM) Mescaline-FLY
References
External links Dimethylmescaline (2,6-Dimethylmescaline) - Isomer Design